Merus Announces Abstracts Accepted For Presentation At The ESMO Asia Congress 2023
Portfolio Pulse from Benzinga Newsdesk
Merus has announced that its abstracts have been accepted for presentation at the ESMO Asia Congress 2023. The presentations will focus on MCLA-129 in combination with osimertinib in treatment naïve, and after progression on osimertinib, non-small cell lung cancer and MCLA-129 in previously treated head & neck squamous cell carcinoma.
October 06, 2023 | 1:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merus' abstracts acceptance for ESMO Asia Congress 2023 could potentially increase visibility and credibility of its MCLA-129 treatment, potentially impacting its stock positively.
The acceptance of Merus' abstracts for presentation at a prestigious event like ESMO Asia Congress 2023 increases the visibility and credibility of its MCLA-129 treatment. This could potentially attract more investors, driving up the demand for its stock and hence its price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100